Get started
Author

Charlotte Poile

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial
2021 · Dean A Fennell, Sean Ewings, et al. · The Lancet Oncology · 256
PDF
Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment
2021 · Min Zhang, Jin-Li Luo, et al. · Nature Communications · 120
PDF
Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial
2021 · Dean A Fennell, Dean A Fennell, et al. · The Lancet Respiratory Medicine · 112
A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study
2021 · Elizabeth K Bancroft, Elizabeth C Page, et al. · The Lancet Oncology · 99
PDF
Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial
2022 · Dean A Fennell, Amy King, et al. · The Lancet Oncology · 78
A randomized phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma.
2021 · Dean Anthony Fennell, Angela Claire Casbard, et al. · Journal of Clinical Oncology · 35
PS01.11 Nivolumab Versus Placebo in Relapsed Malignant Mesothelioma: The CONFIRM Phase 3 Trial
2021 · D. Fennell, C. Ottensmeier, et al. · Journal of Thoracic Oncology · 34
A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma
2024 · Min Zhang, Aleksandra Bzura, et al. · Nature Communications · 33
PDF
Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial
2022 · Dean A. Fennell, Catharine Porter, et al. · EClinicalMedicine · 26
PDF
BAP1 loss induces mitotic defects in mesothelioma cells through BRCA1-dependent and independent mechanisms
2022 · Anita Singh, Sara Busacca, et al. · Oncogene · 15
PDF
Evolutionary characterization of lung cancer metastasis
2026 · Sonya Hessey, Abigail Bunkum, et al. · Nature · 12
PDF
Somatic evolution following cancer treatment in normal tissue
2025 · Oriol Pich, Sophia Ward, et al. · Nature · 11
Author Correction: Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment
2021 · Min Zhang, Jin-Li Luo, et al. · Nature Communications · 11
PDF
Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial
2025 · Dean A. Fennell, Kayleigh Hill, et al. · Nature Communications · 8
PDF
Bemcentinib and pembrolizumab in patients with relapsed mesothelioma: MIST3, a phase IIa trial with cellular and molecular correlates of efficacy.
2023 · Matthew G Krebs, Amy Branson, et al. · Journal of Clinical Oncology · 6
PDF
Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centres
2023 · Dean Fennell, Daniel Griffiths, et al. · BMJ Open · 5
PDF
Gene fusions during the early evolution of mesothelioma correlate with impaired DNA repair and Hippo pathways
2023 · Maymun Jama, Min Zhang, et al. · Genes Chromosomes and Cancer · 5
PDF
MiST1: A phase IIa trial of rucaparib in patients harbouring BAP1/BRCA1 deficient relapsed malignant mesothelioma.
2020 · Dean Anthony Fennell, Liz Darlison, et al. · Journal of Clinical Oncology · 5
Discovery of actionable drug targets to enhance T-cell infiltration and immune checkpoint blockade efficacy in pleural mesothelioma
2025 · Jasper H.L.T. van Genugten, Daniel Faulkner, et al. · Lung Cancer · 3
Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer
2026 · Victoria Gibson, Joanna Dzialo, et al. · Nature Communications · 2
PDF
Abstract CT263: Efficacy and multiomic analysis of Niraparib in relapsed mesothelioma: NERO a randomized phase II trial
2025 · Dean Fennell, Kayleigh Hill, et al. · Cancer Research · 2
Efficacy, cellular and molecular determinants of PD-1 checkpoint inhibition in relapsed mesothelioma.
2023 · Dean Anthony Fennell, Sean Ewings, et al. · Journal of Clinical Oncology · 2
1643TiP First-in-human dose-escalation and expansion study (MITOPE) to evaluate mitochondrial PRX3 inhibition by RSO-021 in patients with mesothelioma and other advanced solid tumors
2022 · S. Dulloo, D.A. Fennell, et al. · Annals of Oncology · 2
Niraparib and dostarlimab efficacy in patients with platinum-sensitive relapsed mesothelioma: MIST5, a phase IIa clinical trial.
2024 · Dean Anthony Fennell, Amy Branson, et al. · Journal of Clinical Oncology · 1
61 The first-in-class peroxiredoxin 3 (PRX3) inhibitor RSO-021 modulates the mesenchymal and immune phenotype in mesothelioma
2024 · Brian Cunniff, Terri Messier, et al. · Lung Cancer · 1
Works count: 54
Citation count: 887
H-index: 11
I10-index: 13
Year
Topic
Type